In their most recent work, Giamarellos-Bourboulis and colleagues examine sepsis-related immune dysfunction by assessing the proinfl ammatory cytokine production capacity in septic patients and healthy volunteers following ex vivo stimulation [1] . A critical examination of their article not only reveals new insights into the possible mechanisms underlying sepsis-related immune system dysfunction, but also highlights the diffi culties inherent in this line of inquiry. Th e authors report that septic patients' isolated leukocytes produced lower amounts of the proinfl ammatory cytokines IL-1β, IL-6 and, to a lesser extent, TNFα when stimulated within 24 hours of Gram-negative sepsis onset. Interestingly, greater severity of sepsis was correlated with a greater degree of impairment. Results were similar in healthy volunteers challenged with lipopolysaccharide, indicating an early shift to an immune-suppressed phenotype following systemic infl ammation.
In our current understanding, an early anti-infl ammatory phenotype following close on the heels of a severe infl ammatory challenge (sepsis, trauma, burn injury, and so forth) acts as a counterweight to the systemic infl ammatory response syndrome and restores immune homeostasis [2] . When short-lived and self-limited, this anti-infl ammatory surge is best termed the compensatory anti-infl ammatory response syndrome (CARS). In some patients, however, CARS is pathologically exaggerated and prolonged (beyond 48 hours). Th is persistent stateknown as immunoparalysis -is associated with increased rates of nosocomial sepsis, multiorgan dysfunction syndrome and death in critically ill patients [3] [4] [5] . Although the features are similar, the distinction between CARS and immunoparalysis is important when contemplating therapy. Th e issue is one of timing: to reverse physiologic CARS too early in the course of illness risks further infl ammatory insult. Th e literature, however, suggests that pathologic immunoparalysis is reversible, to the benefi t of the patient, without iatrogenic hyperinfl am mation [6] [7] [8] .
Although the identifi cation of immunoparalysis, its impact on outcome, and its potential reversibility are becoming increasingly understood, relatively little is known about the cellular and molecular mechanisms driving the process. Previous authors have investigated the mechanisms of immunoparalysis at the transcriptome level [9] [10] [11] . Th is current report makes the case for posttranslational forces as well. In addition to ex vivo cytokine production, Giamarellos-Bourboulis and colleagues examined levels of caspase-1, a protease that cleaves pro-IL-1β into its active form. In their septic patients, reduced IL-1β production capacity was associated with
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Sepsis is now understood to aff ect a variety of changes in the host, chief among them being alterations in immune system function. Proper immune function involves a competent proinfl ammatory response to stimuli as well as a regulated counteracting force to restore homeostasis and prevent systemic infl ammation and organ dysfunction. Broad-spectrum suppression of the infl ammatory response has not been shown to be benefi cial for patients suff ering from septic disease. In fact, sepsis-related immune suppression has become increasingly recognized as an important contributor to late morbidity and mortality in the critically ill. Giamarellos-Bourboulis and colleagues detail the impaired ability of septic patients to produce proinfl ammatory cytokines upon ex vivo stimulation, and introduce altered caspase-1 activity as potentially contributory to this process. Proper understanding of the cellular and molecular events resulting in immune suppression following sepsis is important in the identifi cation of new strategies for treatment and the ideal timing of therapy.
markedly diminished caspase-1 levels. In their healthy volunteers, injection with lipopolysaccharide resulted in lower levels of caspase-1, as well as impaired production of IL-1β. Heretofore, immunoparalysis research has largely centered on the canonical proinfl ammatory cytokine TNFα. (Indeed, assessing ex vivo lipopoly saccharide-induced TNFα production capacity by isolated monocytes is a commonly used method for diagnosing immunoparalysis [2] .) By introducing altered IL-1β biology as a contributory process in the development of CARS/immunoparalysis, the authors lay the ground work for additional avenues of research into the cause(s) or diagnosis of these conditions. Further research is necessary to confi rm a causal link between impaired caspase-1 function and IL-1β production. It is also important to note that, like TNFα, IL-1β is one of myriad proinfl ammatory cytokines whose production and regula tion may be altered in immunoparalysis.
Despite these new and interesting contributions, placing the current work by Giamarellos-Bourboulis and colleagues into proper context is complicated by their study design. Th e early (within 24 hours) sampling window, without additional longitudinal samples, makes it impossible to distinguish patients with physiologic CARS from those with pathologic immunoparalysis. Previous evidence has shown that only patients unable to reverse an early anti-infl ammatory phenotype by 3 to 4 days are at increased risk of poor outcome [3] . An early anti-infl ammatory phenotype (possible CARS) is thus apparently not as concerning as prolonged immune suppression (probably immunoparalysis). Unfortunately, the mecha nisms or predispositions mediating the transition from CARS to immunoparalysis are currently unknown.
Th e work by Giamarellos-Bourboulis and colleagues, and that of many other researchers, seeks to uncover the events surrounding sepsis-related immune system dysfunc tion. By understanding the mechanisms involved, such as altered caspase-1 action, novel therapeutic targets may be identifi ed. Th rough careful targeting of therapy to those patients with true immunoparalysis, the best chance for improved outcomes will be realized.
Abbreviations CARS, compensatory anti-infl ammatory response syndrome; IL, interleukin; TNF, tumor necrosis factor.
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